ArticleFrontiers in immunology2026

Residual disease subtyping predicts survival and guides adjuvant immunotherapy in esophageal squamous cell carcinoma after neoadjuvant chemoimmunotherapy.

Huiya Wang et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.